AMRX vs IT · P/E 44, rev $2.79B vs P/E 16, rev $6.27B
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) versus Gartner Inc (IT) — a side-by-side from cached financials, not a winner call.
Amneal Pharmaceuticals, Inc. Class A Common Stock (AMRX) is a drug manufacturers - specialty & generic company listed on NASDAQ.
Gartner Inc (IT) is a information technology services company listed on US.
Latest reported AMRX revenue for 2024-12-31 was $2.79B. Net income was -$73.9M. Revenue was up 16.7% from 2023-12-31 to 2024-12-31. AMRX currently screens at market cap $5.19B and trailing P/E 44.0.
Latest reported IT revenue for 2024-12-31 was $6.27B. Net income was $1.25B. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. IT currently screens at market cap $11.03B and trailing P/E 16.3.
AMRX currently screens at market cap $5.19B and trailing P/E 44.0. IT currently screens at market cap $11.03B and trailing P/E 16.3.
Not investment advice. Open the AMRX and IT stock pages for the full models.
Not investment advice.